Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study
One year of anti-CGRP mAbs therapy yields a ≥ 75% response in over two-thirds and a 100% response in nearly one-quarter of patients with HFEM or CM and prior treatment failures. Most super- and absolute responses emerge after six months, supporting long-term continuation treatment.
Authors
- Massimo Filippi (ORCID: https://orcid.org/0000-0002-5485-0479)
- Cinzia Aurilia (ORCID: https://orcid.org/0000-0002-2658-2243)
- Piero Barbanti (ORCID: https://orcid.org/0000-0002-5670-3755)
- Roberta Messina (ORCID: https://orcid.org/0000-0003-4421-0432)
- Davide Mascarella (ORCID: https://orcid.org/0000-0002-9265-3281)
- Sabina Cevoli (ORCID: https://orcid.org/0000-0003-4668-4295)
- Stefano Bonassi (ORCID: https://orcid.org/0000-0003-3833-6717)
- Paola Torelli (ORCID: https://orcid.org/0000-0002-4072-2353)
- Gabriella Egeo (ORCID: https://orcid.org/0000-0003-3068-4522)
- Stefania Proietti (ORCID: https://orcid.org/0000-0002-9844-1482)
- Giulia Fiorentini
Institutions
- University of Parma (IT)
- Vita-Salute San Raffaele University (IT)
- San Raffaele University of Rome (IT)
- Istituto delle Scienze Neurologiche di Bologna (IT)
- IRCCS Ospedale San Raffaele (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- European Automobile Manufacturers Association (BE)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1007/s00415-025-13419-z
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Ministero della Salute